8ISIS 2 (Second International Study of Infarct Survival)Collabotative Group.Randomized trial of intravenous streptokinase,oral asprin,both or neither among 17 187 cases of suspected acute myocardial infarction.ISIS 2[J].Lancet,1988,2:349-360.
9The FRISCⅡ investigators .Invasive compared with non-invasive treatment in unstable coronary disease: FRISCⅡprospectiverandomized multicentre study[J].Lancet,1999,354:708-715.
10Holmvang L,Clemmensen P,Lindahl P,et al.Ischemic burden in standard EKG identifics who benefit most from an early invasive strategy in unstable coronary artery disease:A FRISCⅡstudy[J].J Am Coll Cardiol,2001,37:341A.
1Chen ZM, Jiang LX,Chen YP, et al. Addition of clopidogrel toaspirin in 45,852 patients with acute myocardial infarction;randomized placebo-controlled trial〔J〕. Lancet, 2005, 366:1607-1621.
2Payne CD, Li YG, Small DS,ei al. Increased active metabolitefor mat ion explains the greater platelet inhibition with prasug-rel com-pared to high-dose clopidogrel〔J〕. J Cardiovasc Phar-maco)2007.50: 555-562.
3Gurbel PA’Bliden KP,Butler K,etal. Randomized doubleblindassessment of the ONSET and OFFSET of the antiplateleteffects of ticagrelor versus clopidogrel in patients with stablecoronary artery disease: the ONSET/OFFSET studyCJD. Circu-lation, 2009 ,120(25): 2577-2585.
4Wallentin L. Becker R C,Budaj Ayet al. Ticagrelor versus clo-pidogrel in patients with actue coronary syndromes [J]. N EnglJ Med,2009,361(11) :1045-1057.
5Biondi-zoccai G. Lotrionte M,Gaita Ffet al. Adjusted indirectcomparison meta-analysis of prasugrel versus ticagrelor for pa-tients with acute coronary syndromes CJ^l. Int J Cnrdiol, 2011,150(3):325-331.
6Ramaraj R, Movahed ME, Hashemzadeh M Novel antiplateletagent ticagrelor in the management of acute coronary syndrome[J]_ J Irzterv Carddol, 2011,24(3) :199-207.
7Connolly SJE, Michael D, Yusuf SE, et al. Dabigatran versusWarfarin in Patients with Atrial Fibrillation CJD. New EnglandJournal of Medicine,2009,361(12) : 1139-1151.
8Athyros VG,TziomaIos K,Gossios TDfet al. Safety and effica-cy of long-term statin treatment for cardiovascular events in pa-tients with coronary heart disease and abnormal liver tests inthe Greek Atorvastatin and Coronary Heart EHsease Evaluation(GREACE)Study: A post-hoc analysisCJD. Lancet, 2010, 376(9756):1916-1922.
9Musunuru K,Blumenthal RS. The implications of the ezetimi-be and simvastatin in hypercholesterolemia enhances athero-sclerosis regression trial: a return to first principles〔J〕. CHnCardiol 12008,31 (6) : 288-290.
10Dudek D,Onuma Y.Ormiston JA^etal. Four-year clinical fol-low-up of the ABSORB everolimus-eluting bioresorbable vas-cular scaffold in patients with denovo coronary artery disease:the ABSORB trial〔J〕. Euro Intervention, 2011,7 (9): 1060-1061.
